pimobendan has been researched along with Cardiomyopathy, Hypertrophic Obstructive in 5 studies
pimobendan: produces arterial & venous dilatation in dogs; structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "The benefits of pimobendan in the treatment of congestive heart failure (CHF) in cats with hypertrophic cardiomyopathy (HCM) have not been evaluated prospectively." | 9.41 | Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study. ( Glaus, T; Lehmkuhl, L; Loureiro, J; Luis Fuentes, V; MacGregor, J; Mohren, N; Rush, JE; Sayer, MP; Schober, KE; Summerfield, NJ; Wess, G; Wright, K, 2021) |
| "To assess survival time and adverse events related to the administration of pimobendan to cats with congestive heart failure (CHF) secondary to hypertrophic cardiomyopathy (HCM) or hypertrophic obstructive cardiomyopathy (HOCM)." | 7.80 | Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure. ( Ames, MK; Atkins, CE; DeFrancesco, TC; Hodge, TE; Keene, BW; Meurs, KM; Reina-Doreste, Y; Stern, JA; Tou, SP, 2014) |
| "The benefits of pimobendan in the treatment of congestive heart failure (CHF) in cats with hypertrophic cardiomyopathy (HCM) have not been evaluated prospectively." | 5.41 | Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study. ( Glaus, T; Lehmkuhl, L; Loureiro, J; Luis Fuentes, V; MacGregor, J; Mohren, N; Rush, JE; Sayer, MP; Schober, KE; Summerfield, NJ; Wess, G; Wright, K, 2021) |
| "To assess survival time and adverse events related to the administration of pimobendan to cats with congestive heart failure (CHF) secondary to hypertrophic cardiomyopathy (HCM) or hypertrophic obstructive cardiomyopathy (HOCM)." | 3.80 | Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure. ( Ames, MK; Atkins, CE; DeFrancesco, TC; Hodge, TE; Keene, BW; Meurs, KM; Reina-Doreste, Y; Stern, JA; Tou, SP, 2014) |
| "Pimobendan was well tolerated in the acute setting in cats with HCM." | 1.62 | Acute pharmacodynamic effects of pimobendan in client-owned cats with subclinical hypertrophic cardiomyopathy. ( Fousse, SL; Oldach, MS; Ontiveros, ES; Stern, JA; Ueda, Y; Visser, LC, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kochie, SL | 1 |
| Schober, KE | 2 |
| Rhinehart, J | 1 |
| Winter, RL | 1 |
| Bonagura, JD | 1 |
| Showers, A | 1 |
| Yildez, V | 1 |
| Rush, JE | 1 |
| Luis Fuentes, V | 1 |
| Glaus, T | 1 |
| Summerfield, NJ | 1 |
| Wright, K | 1 |
| Lehmkuhl, L | 1 |
| Wess, G | 1 |
| Sayer, MP | 1 |
| Loureiro, J | 1 |
| MacGregor, J | 1 |
| Mohren, N | 1 |
| Oldach, MS | 1 |
| Ueda, Y | 1 |
| Ontiveros, ES | 1 |
| Fousse, SL | 1 |
| Visser, LC | 1 |
| Stern, JA | 2 |
| Reina-Doreste, Y | 1 |
| Keene, BW | 1 |
| Tou, SP | 1 |
| Atkins, CE | 1 |
| DeFrancesco, TC | 1 |
| Ames, MK | 1 |
| Hodge, TE | 1 |
| Meurs, KM | 1 |
| White, AJ | 1 |
2 trials available for pimobendan and Cardiomyopathy, Hypertrophic Obstructive
| Article | Year |
|---|---|
Effects of pimobendan on left atrial transport function in cats.
Topics: Animals; Atrial Function, Left; Cardiomyopathy, Hypertrophic; Cat Diseases; Cats; Cohort Studies; He | 2021 |
Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study.
Topics: Animals; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cat Diseases; Cats; Dog Diseases; Dogs; H | 2021 |
3 other studies available for pimobendan and Cardiomyopathy, Hypertrophic Obstructive
| Article | Year |
|---|---|
Acute pharmacodynamic effects of pimobendan in client-owned cats with subclinical hypertrophic cardiomyopathy.
Topics: Animals; Blood Flow Velocity; Blood Pressure; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cat | 2021 |
Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure.
Topics: Animals; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Case-Control Studies; Cat Diseases; Cats; | 2014 |
End-stage hypertrophic cardiomyopathy in a cat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Arrhythmia Agents; Atenolol; Benzazepines; C | 2015 |